Gilead Sciences (GILD) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

• 7/12/2026 – Gilead Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/8/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $168.00 to $166.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – Gilead Sciences had its price target lowered by Royal Bank Of Canada from $122.00 to $120.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Gilead Sciences had its price target lowered by Truist Financial Corporation from $157.00 to $156.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Gilead Sciences was upgraded by HSBC Holdings plc from “hold” to “buy”. They now have a $155.00 price target on the stock, up from $133.00.
• 7/6/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 6/16/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 6/9/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – Gilead Sciences had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 6/1/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Royal Bank Of Canada. They now have a $122.00 price target on the stock.
• 6/1/2026 – Gilead Sciences was upgraded by Royal Bank Of Canada from “hold” to “moderate buy”.
• 5/28/2026 – Gilead Sciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 5/20/2026 – Gilead Sciences was upgraded by Maxim Group from “hold” to “buy”. They now have a $165.00 price target on the stock.
• 5/19/2026 – Gilead Sciences had its price target lowered by Daiwa Securities Group Inc. from $161.00 to $150.00. They now have an “outperform” rating on the stock.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 77,000 shares of company stock worth $9,978,740. Insiders own 0.30% of the company’s stock.

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.